Nektar Therapeutics NKTR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.86M-50.2% | $21.81M+85.0% | $11.79M+5.5% | $11.18M+6.8% | $10.46M-64.1% | ||
| —— | $21.81M+85.0% | $11.79M+5.5% | $11.18M+6.8% | $10.46M-50.7% | ||
| $35.68M+20.1% | $29.71M+9.0% | $27.25M-8.8% | $29.89M-1.9% | $30.48M+6.0% | ||
| $13.44M+20.2% | $11.19M-30.4% | $16.07M-5.9% | $17.07M-29.9% | $24.35M+42.1% | ||
| $49.92M+0.9% | $49.47M+13.8% | $43.46M-8.3% | $47.41M-13.8% | $55M+271% | ||
| -$39.05M-41.2% | -$27.67M+12.7% | -$31.67M+12.6% | -$36.23M+18.6% | -$44.54M— | ||
| -359.6%-233pp | -126.9%+142pp | -268.6%+55.6pp | -324.2%+102pp | -425.8%— | ||
| -$4.04M+42.6% | -$7.04M-110% | -$3.35M-5.8% | -$3.17M-72.6% | -$1.83M+75.0% | ||
| -$43.09M-24.2% | -$34.7M+0.9% | -$35.02M+11.1% | -$39.4M+15.0% | -$46.37M— | ||
| $64K— | —— | -$33K+82.4% | -$188K-462% | $52K+120% | ||
| -$44.9M-24.5% | -$36.08M-1.6% | -$35.52M+14.6% | -$41.59M+18.3% | -$50.88M— | ||
| -413.4%-248pp | -165.4%+136pp | -301.3%+70.9pp | -372.2%+114pp | -486.4%-486pp | ||
| -$1.82-14.5% | -$1.59+15.0% | -$1.87+36.6% | -$2.95+18.5% | -$3.62-74.9% | ||
| -$38.9M-41.6% | -$27.48M+12.7% | -$31.48M+12.6% | -$36.02M+18.3% | -$44.11M-13,386% | ||
| -358.2%-232pp | -126%+141pp | -267%+55.3pp | -322.3%+99.4pp | -421.7%-423pp | ||
| -$39.05M-41.2% | -$27.67M+12.7% | -$31.67M+12.6% | -$36.23M+18.6% | -$44.54M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Nektar Therapeutics's revenue?
- Nektar Therapeutics (NKTR) generated $55.6M in revenue over the trailing twelve months, down 36.2% year over year.
- Is Nektar Therapeutics profitable?
- Nektar Therapeutics is not currently profitable: it reported a net loss of $158.1M over the trailing twelve months, a -284.2% net margin.
- What are Nektar Therapeutics's profit margins?
- Gross margin is 100.0% and operating margin is -242.0%, with a -284.2% net margin.
- What is Nektar Therapeutics's earnings per share?
- Nektar Therapeutics's diluted EPS over the trailing twelve months is $-8.23.
- Where does Nektar Therapeutics's income statement data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
